Plus Therapeutics reports FY23 EPS ($4.24) vs ($11.58) last year

The Company’s cash balance was $8.6M at December 31 compared to $18.1M at December 31..”Based on 2023 achievements and planned 2024 milestones, we intend to move our lead targeted radiotherapeutic into registrational trials in 2025,” said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics. “Our ReSPECT clinical trials in both LM and recurrent glioblastoma rGBM continue to demonstrate encouraging safety and efficacy signals for rhenium obisbemeda and we plan U.S. Food and Drug Administration meetings during 2024 to discuss next steps toward product approval.”